Proinsulin-Transferrin Fusion Protein – a Novel Long-acting Insulin Analogue

ProINS-Tf exhibited a slow, but sustained, in vivo hypoglycemic efficacy and long plasma half-life. Thus, ProINS-Tf fusion protein can potentially be administered as a prodrug with sustained Tf-mediated activation and selectivity in inhibiting hepatic glucose production (Diabetes)